Cargando…
Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
Autores principales: | Zhao, Ming, Chen, Jiayi, Yuan, Yanyan, Zou, Zuquan, Lai, Xiaolong, Rahmani, Daud M, Wang, Fuyan, Xi, Yang, Huang, Qin, Bu, Shizhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701236/ https://www.ncbi.nlm.nih.gov/pubmed/29176726 http://dx.doi.org/10.1038/s41598-017-16510-2 |
Ejemplares similares
-
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
por: Zhao, Ming, et al.
Publicado: (2017) -
Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Correction: Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012) -
Author Correction: Pectin as an Extraordinary Natural Kinetic Hydrate Inhibitor
por: Xu, Shurui, et al.
Publicado: (2020)